483
POINT Biopharma USA Inc.POINT Biopharma USA Inc. – FDA 483, Jun 7, 2024
Record Details
POINT Biopharma USA Inc. in Indianapolis, IN, a sterile radioactive drug manufacturer, was inspected from May 29 to June 7, 2024. The inspection revealed a significant failure to test samples of each component for identity and conformity with specifications. Additionally, the firm failed to validate and establish the reliability of its component supplier's test analyses, relying on Certificates of Analysis without proper verification.
View Company Profile
ID · 530b5998-d13e-4471-9be4-0fce34b92ddf
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.